An official website of the United States government
Home
Name
Besponsa
Alternate Names
Inotuzumab ozogamicin
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
A CD22-targeted cytotoxic immunoconjugate
NSC Number
None
Primary Site
None
Histology
Remarks
March 6, 2024 The FDA approved inotuzumab ozogamicin (Besponsa) for pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).
August 17, 2017 The FDA approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Besponsa is a targeted therapy that is thought to work by binding to B-cell ALL cancer cells that express the CD22 antigen, blocking the growth of cancerous cells.
August 17, 2017 The FDA approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Besponsa is a targeted therapy that is thought to work by binding to B-cell ALL cancer cells that express the CD22 antigen, blocking the growth of cancerous cells.
Coding
This drug should be coded
